logo
  

Synopsys To Sell Software Integrity Group Business For $2.1 Bln

Synopsys, Inc. (SNPS), an electronic design automation company, said on Monday that it has inked a deal with Clearlake Capital Group, L.P. and Francisco Partners, two private equity firms, to sell its Software Integrity Group business for up to $2.1 billion.

The transaction, expected to be closed in the second-half, includes up to $475 million in cash payable upon the achievement by Francisco Partners and Clearlake, of specified rate of return in connection with one or more liquidity transactions.

Sassine Ghazi, CEO of Synopsys, said, "For Synopsys, this move sharpens our focus on the unprecedented, high-growth opportunity we have in our core business- where the engineering of silicon and systems is converging as technology R&D teams look to capitalize on this AI-driven era of pervasive intelligence."

Post-transaction, the newly formed privately-held business will serve as an independent application security testing software provider, led by the existing Software Integrity Group management team.

The name of the new standalone entity will be announced at a later date.

SNPS was trading up by 1 percent at $542.30 in the pre-market trade on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT